oncology
GU

Olaparib PBS listed for first-line maintenance in advanced ovarian cancer

More women with ovarian cancer will gain access to olaparib (Lynparza) after its PBS listing is expanded to include first-line maintenance therapy from 1 November. The PARP inhibitor has been available on the PBS since 2017 to women whose BRCA-mutated, stage 3 and 4 platinum sensitive ovarian cancer had relapsed. Under an expended listing it ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic